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Abstract 
 
Current therapeutic options for the pediatric cancer rhabdomyosarcoma (RMS) 
have not improved significantly, especially for metastatic RMS. In the present work, we 
performed a deep microRNA profiling of the three major human RMS subtypes, along 
with cell lines and normal muscle, to identify novel molecular circuits with therapeutic 
potential. The signature we determined could discriminate RMS from muscle, revealing a 
subset of muscle-enriched microRNA (myomiR), including miR-22 which was strongly 
underexpressed in tumors. miR-22 was physiologically induced during normal myogenic 
differentiation and was transcriptionally regulated by MyoD, confirming its identity as a 
myomiR. Once introduced into RMS cells, miR-22 decreased cell proliferation, 
anchorage-independent growth, invasiveness and promoted apoptosis. Moreover, 
restoring miR-22 expression blocked tumor growth and prevented tumor dissemination in 
vivo. Gene expression profiling analysis of miR-22-expressing cells suggested TACC1 
and RAB5B as possible direct miR-22 targets. Accordingly, loss and gain of function 
experiments defined the biological relevance of these genes in RMS pathogenesis. 
Finally, we demonstrated the ability of miR-22 to intercept and overcome the intrinsic 
resistance to MEK inhibition based on ERBB3 upregulation. Overall our results 
identified a novel miR-22 regulatory network with critical therapeutic implications in 
RMS. 
  
 
 
5 
 
Introduction 
 
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene 
expression at the post-transcriptional level (1,2). In the last decade, the critical role of 
miRNAs has been reported in a wide range of biological functions including cell 
proliferation, migration, apoptosis, lineage commitment and differentiation (3,4). Thus it 
is not surprising that miRNAs are frequently dysregulated in cancer, where they can act 
either as oncogenes or oncosuppressors depending on their downstream target genes (5). 
Furthermore, miRNA signatures have been successfully used to classify human cancers 
and to discover novel attractive targets for therapeutic intervention (6). 
 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood 
and the third one in young adults (7). Histopathological classification includes three 
major subtypes: embryonal (ERMS), alveolar (ARMS) and pleomorphic (PRMS). ERMS 
are more frequent, genetically heterogeneous and associated with a better prognosis (8–
10). Conversely ARMS are less common and more aggressive, with a worse outcome. A 
dismal clinical prognosis is genetically ascribed to the PAX3/7-FKHR translocation 
present in more than 80% of cases (11). Notably, RMS cells are positive for myogenic 
markers and resemble normal muscle progenitors but are unable to complete the 
differentiation program (12). We have previously showed that the muscle-enriched 
miRNAs miR-1 and miR-206 (myomiRs) reprogram the RMS expression profile toward 
that of a normal muscle, in a process involving the post-transcriptional regulation of 
hundreds of genes, among which MET, G6PD, ACTL6A and SMYD1 (13–15). 
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In this work we used a next-generation miRNA sequencing approach (NGS) on a 
large panel of human RMS primary tumors, including the three major subtypes, cell lines 
and normal muscle tissues, to identify novel miRNA regulatory circuits involved in RMS 
pathogenesis. The miRNA signature clearly distinguished malignant tissues from normal 
skeletal muscle and revealed a strong reduction of miR-22 and miR-378 in RMS. 
However, only the rescue of miR-22 exerted a very potent oncosuppressor function, 
interfering with the transformed properties of RMS cells both in vitro and in vivo. Gene 
expression profiling of miR-22-expressing RMS cells suggested TACC1 and RAB5B as 
two critical miR-22 targets, while ERBB3 emerged only upon treatment of mutant 
NRAS-positive cells with MEK inhibitors. Altogether our NGS miRNA sequencing 
effort uncovered a novel miR-22 oncosuppressor regulatory circuit that opposes RMS 
tumor growth and interferes with the resistance to MEK inhibition. 
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Materials and Methods 
 
Cell lines  
Embryonal (RD18, CCA, HTB82, TE671, indicated as Myosarcoma_TE) and alveolar 
(RH4, RH30) RMS cell lines were provided by Dr. Pier-Luigi Lollini (University of 
Bologna, Bologna, Italy). The pleomorphic cell line RMS-559 was obtained from Samuel 
Singer’s lab. HTB82 and TE671 cell lines were originally obtained from ATCC 
(Manassas, VA, USA); RH30 and RH4 (RH41) were originally obtained from DSMZ 
(Braunschweig, Germany); CCA and RD18 cell lines were originally stabilized in Pier-
Luigi Lollini’s lab. C2C12 myoblasts were originally obtained from DSMZ 
(Braunschweig, Germany). Satellite cells, RD18 NpBI-206 cells, RD18 NpBI-206AS 
cells and NIH 10T½ NpBI-MyoD cells were previously described (13–15). RMS cell 
lines, NIH 10T½ cells, satellite cells and myoblasts were grown as previously described 
(13). RD18, HTB82, TE671, RH4 and RH30 cell lines were routinely authenticated 
(every six months) by short tandem repeat (STR) analysis. CCA cell line, for which STR 
profile is unknown, was authenticated by sequencing of the KRAS Q61L mutation.  
 
Patients 
Primary human tumors of embryonal, alveolar and pleomorphic histology (or their RNA) 
and muscle tissues were obtained from Memorial Sloan Kettering Cancer Center, New 
York, NY, USA, with informed consent prior to the inclusion in the study and with 
obscured identity, according to the recommendations of the Institutional Review Board of 
the Memorial Sloan Kettering Cancer Center. For all ARMS samples, the presence of the 
 
 
8 
 
specific fusion transcripts was confirmed by RT-PCR. Of the 14 RMS included in this 
study, 10 had previously been extensively analyzed by gene expression profiling, 
confirming subtype-specific signatures (16). Normal cell contamination of the processed 
specimens was reviewed and assessed to be less than 20%. 
 
Small RNA isolation and library generation 
RNA from cultured cells, freshly frozen and OCT-embedded tissues was extracted using 
Trizol (Invitrogen). RNA from formalin-fixed, paraffin-embedded tissues was isolated 
with MasterPure RNA Purification Kit (Epicentre Biotechnologies). Despite a different 
yield of total RNA, the miRNA expression profiles of all types of samples are well 
correlated across the various histological subtypes. cDNA libraries preparation was 
performed as previously described (17). A brief explanation can be found in 
Supplementary Materials and Methods. Sequencing was performed at Memorial Sloan 
Kettering Cancer Center and raw data are deposited on SRA platform, ID PRJNA326118. 
Computational analysis of the raw data was done in collaboration with Mihaela Zavolan’s 
lab, University of Basel, Switzerland.  
 
Lentiviral vectors and siRNAs 
NpBI-22 and NpBI-378 vectors were generated as previously described (13). Vectors and 
si/shRNAs are detailed in Supplementary Materials and Methods.  
 
Northern blot 
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Northern blot analysis was performed as previously described (13). 32P-labeled DNA 
oligos are listed in Supplementary Materials and Methods. 
 
Microarrays and data analysis 
Affymetrix Human GeneChip Gene ST 1.0 arrays (Affymetrix) were hybridized at the 
Cogentech core facility (Milano, Italy) according to standard Affymetrix protocols.  The 
array data were analyzed with the Partek Genomics Suite. All genes showing differential 
expression between the 2 experimental conditions found to be significant by ANOVA 
were then subjected to unsupervised hierarchical clustering. Microarray data were 
deposited under series GSE83805.  
 
Sensor vector generation and reporter assays 
GFP/luciferase reporter vectors were co-transfected with synthetic pre-miRNA (miRNA 
precursor hsa-miR-22, PM10203, ThermoFisher) in HEK 293T cells. For MyoD binding 
sites validation, luciferase reporter vectors were transfected in NIH 10T½ NpBI-MyoD 
cells. Detailed information is summarized in Supplementary Materials and Methods.  
 
Real-time PCR analysis 
Taq-Man miRNA Assays (Applied Biosystems) were used for relative quantification of 
mature miRNAs. MiR-16 was used to normalize the results. Gene expression was 
evaluated as previously described (15), using primers listed in Supplementary Materials 
and Methods. HuPO was used to normalize the results.  
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Cell proliferation assay, cell cycle analysis and assessment of apoptosis 
For proliferation assay, cells were plated in 24-well plates at a density of 5×103 per well. 
Proliferation was evaluated by CellTiter-Glo (Promega) following the manufacturer‘s 
instructions. Cell cycle analysis and apoptosis were performed as previously described 
(13). 
 
Anchorage-independent cell-growth, invasiveness and scratch wound assays 
Soft-agar assay was performed as previously described (13). After 2 weeks or one month 
in culture colonies were counted and images were acquired at 5X magnification. 
Invasiveness was examined using a membrane invasion culture system (Corning Life 
Sciences) as previously described (13). Scratch wound assay is detailed in Supplementary 
Materials and Methods. 
 
Western blot, FACS and immunohistochemistry 
Western blot assay, MHC immunostaining for FACS analysis and immunohistochemistry 
were performed as previously described (13,15). All antibodies used are listed in 
Supplementary Materials and Methods.   
 
Chromatin immunoprecipitation assay 
ChIP assay was performed as previously described (18). Antibodies and primers are listed 
in Supplementary Materials and Methods.  
 
Inhibitors 
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Selumetinib (AZD6244, Selleckchem) and Lapatinib (GW-572016, Selleckchem) were 
used at 1µM. DMSO was used as a control. 
 
In vivo tumorigenesis assay 
For in vivo tumor growth, cells were resuspended in sterile PBS and injected 
subcutaneously into the flank or in the tail vein of female nu/nu mice (Charles River 
Laboratories). Tumor size was measured as previously described (13). Conditional miR-
22 expression was induced in mice by administration of 1 mg/ml of doxycycline in the 
drinking water. All animal procedures were approved by the Ethical Committee of the 
University of Turin and by the Italian Ministry of Health. 
 
Statistical analysis 
Two-tailed paired or unpaired Student‘s t test was used to evaluate statistical 
significance: NSP>0.05; *P<0.05; **P<0.01; ***P<0.001. All mean values are expressed 
as SD or SEM, as specified in figure legends, and derive from at least three independent 
experiments. 
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Results 
 
Small RNA cloning and deep sequencing reveal a distinct miRNA signature in RMS 
compared to normal muscle 
To identify novel miRNAs involved in RMS pathogenesis, we profiled miRNA 
expression in 21 primary human RMS and 4 normal muscles by NGS of small RNA 
libraries. Unsupervised hierarchical clustering showed a strong distinction between 
muscles and tumors (Fig. 1A, Supplementary Fig. S1A and Supplementary Table S1), 
revealing a clear RMS-related miRNA signature and indicating a profound miRNA 
dysregulation in malignant tissues. However, miRNA profiling did not distinguish among 
ERMS, ARMS and PRMS, indicating that miRNAs cannot be predictive of specific 
subtypes. Notwithstanding, we identified few families overrepresented in tumor samples 
(including miR-130a and miR-335-5p; Fig. 1A), and not expressed in muscle. As 
expected, myomiRs (miR-1/206/133) were particularly underexpressed in RMS (Fig. 1A, 
Supplementary Fig. S1A and Supplementary Tables S1 and S2), confirming the good 
reliability of our signature.    
Interestingly, in the top 5 muscle-enriched miRNAs we detected also miR-378 and 
miR-22 (Fig. 1A and Supplementary Table S2). While miR-378 has been recently 
associated to RMS pathogenesis (19), the role of miR-22 has remained so far unexplored. 
 
miR-22 and -378 are muscle-enriched miRNAs 
We first validated miR-22 and miR-378 expression levels using alternative 
approaches. Northern blot analysis confirmed the enrichment of miR-22 and miR-378 in 
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normal muscle, while both were barely detectable in primary RMS (Fig. 1B). 
Furthermore, we assessed their presence and induction in different myogenic systems: 
differentiated satellite cells and C2C12 myoblasts, miR-206-expressing RMS cells (13) 
and MyoD-reprogrammed 10T½ fibroblasts (15). In all models used and as previously 
reported for miR-22 in C2C12 myoblasts (20), miR-22 and -378 were strongly induced 
during differentiation (Fig. 1C-F), suggesting the involvement of both miRNAs in the 
myogenic program. Notably, for both miRNAs there is complete homology in the mature 
sequence of human and mouse, suggesting conserved functions. Interestingly, we did not 
observe any substantial difference of expression between the two miRNAs in 
differentiated satellite cells and myoblasts. However, miR-378 was the most upregulated 
miRNA in MyoD-reprogrammed 10T½ fibroblasts, whereas miR-22 was particularly 
induced in miR-206-expressing RMS cells. Thereby, both miRNAs are involved in the 
myogenic program but miR-22 may exert a critical role in RMS.  
 
miR-22 acts as a potent oncosuppressor by interfering with the transformed 
properties of RMS cells 
To investigate the role of the two newly identified muscle-enriched miRNAs in 
RMS pathogenesis, we generated RMS cells that conditionally expressed miR-22 or -378 
in a Doxycycline (Dox) -dependent manner. The system was tightly Dox-regulated with 
no expression in normal medium, while Dox administration resulted in a robust miRNA 
induction comparable to that observed in mouse skeletal muscle, especially for miR-22 
(Supplementary Fig. S2A and B). MiR-22 induction arrested proliferation of both ERMS 
(RD18) and ARMS (RH30) cells (Fig. 2A and B). Accordingly, cell cycle distribution 
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analysis showed a reduction in the S phase and a concomitant accumulation in the G0/G1 
and in G2/M phases of the cell cycle (Fig. 2C and D). Furthermore, miR-22 promoted 
apoptosis both in ERMS and ARMS cells (Fig. 2E and F). These two aspects were 
confirmed by changes in expression of proteins involved in cell proliferation and 
apoptosis (Fig. 2G). We next investigated the ability of miR-22 to interfere with the 
transformed properties of RMS cells. Long-term miR-22 induction significantly impaired 
anchorage-independent growth in soft-agar (Fig. 2H and I). Moreover, miR-22 expression 
impaired invasiveness in matrigel assays (Fig. 2J and K). 
Interestingly, miR-22 is hosted in the second exon of a long non-coding RNA 
(lncRNA, MIR22HG). Thus, to rule out the possibility that part of the oncosuppressor 
potential observed was associated to the lncRNA, we generated a vector expressing the 
same miR-22 precursor, but with the miR-22 seed sequence completely mutagenized. 
Using this construct, we did not observe mature miR-22 production nor an effect on RMS 
cell proliferation (Supplementary Fig. S2C and D). Finally, we also explored the 
oncosuppressor potential of miR-378. Differently from miR-22, miR-378 was, in our 
setting, less effective in interfering with the transformed features of RMS cells 
(Supplementary Fig. S2E-G and data not shown). Thus, we decided to further investigate 
the biological relevance of miR-22 only.  
 
MyoD binds to the promoter region of miR-22 at the onset of myogenic 
differentiation and activates its transcription 
The observation that miR-22 was upregulated during myogenic cell differentiation 
suggested that muscle regulatory factors might be responsible for its activation. MyoD is 
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the master transcription factor that governs the myogenic program (21). We therefore 
examined the core promoter of miR-22, consisting of 1200 bp and we identified four 
predicted MyoD recognition sites, conserved in the mouse and human genes (Fig. 3A, 
black boxes). Thus we set up a ChIP assay on MyoD-reprogrammed 10T½ fibroblasts. As 
expected, MyoD and acetyl-histone H3 binding at the miR-22 core promoter regions was 
observed only upon MyoD induction (Fig. 3B and C). To verify whether MyoD binding 
resulted in transcriptional activity, we generated three sensor constructs (sensor 22.0, 22.1 
and 22.2) containing 419, 586 and 1089 bp upstream of pre-miR-22 fused to a luciferase 
reporter. Upon MyoD induction, only sensors 22.1 and 22.2, containing two and four 
putative MyoD binding sites respectively, displayed strong transcriptional activity (Fig. 
3D). Notwithstanding, no significant difference in luciferase induction was observed 
between the 22.1 and 22.2 constructs, indicating that the first two putative sites, located on 
the 22.1 fragment, were mainly responsible for MyoD binding. Accordingly, mutation of 
both E-boxes (I+II) of the 22.1 construct completely abolished luciferase induction (Fig. 
3D), indicating that these two regulatory elements are essential for MyoD transcriptional 
activity. 
We previously showed that miR-206, another MyoD-transcriptionally regulated 
myomiR (22), is able to force RMS cells to resume differentiation (13). However, when 
we explored the myogenic potential of miR-22, we did not observe any sign of terminal 
RMS differentiation (Supplementary Fig. S3A and B). Considering that MyoD promotes 
myogenic differentiation by first arresting myoblast proliferation and subsequently by 
driving terminal differentiation, it is likely that miR-22 is involved only in the MyoD-
dependent cell cycle arrest. 
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miR-22 abrogates tumor growth and dissemination 
The ability of miR-22 to act as a potent oncosuppressor encouraged us to explore 
its therapeutic potential in vivo. We first assessed whether miR-22 was sufficient to 
prevent tumor growth. To this aim, engineered RMS cells were injected into 
immunocompromised mice that were immediately treated with doxycycline. While in 
control mice tumors grew rapidly, miR-22 induction completely abolished RMS formation 
(Fig. 4A). Then we evaluated the therapeutic potential of miR-22 by inducing the miRNA 
only after the tumor became palpable. Also in this case miR-22 expression resulted in 
potent inhibition of RMS growth (Fig. 4B). The anti-tumorigenic effect of miR-22 was 
confirmed by reduction of Ki67 staining and by the presence of cleaved Caspase-3-
positive cells in treated mice (Fig. 4C). Lastly, we tested miR-22 ability to interfere with 
RMS cell dissemination. Tail vein injection of non-induced cells resulted in their rapid 
dissemination in lungs and kidneys (Fig. 4D and E, NI). Conversely, miR-22 induction 
fully inhibited macro and micro metastasis formation in both organs (Fig. 4D and E, IND). 
Immunohistochemistry analysis confirmed the presence of actively proliferating tumor 
cells only in tissues obtained from control mice (Fig. 4D and E). 
 
Gene expression profiling of miR-22-expressing RMS cells identifies TACC1 and 
RAB5B as two critical targets 
To investigate the mechanism by which miR-22 interfered with the transformed 
properties of RMS cells, we compared gene expression profiling of RD18 NpBI-22 
induced (IND) cells with non-induced (NI) cells. Unsupervised hierarchical clustering 
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resulted in a dendrogram with two clearly distinct branches separating miR-22-expressing 
cells from controls (Supplementary Fig. 4A). In particular, ANOVA analysis revealed a 
total of 494 significantly modulated transcripts, among which 263 were downregulated in 
the induced condition. To identify possible miR-22 target genes we analyzed the 
downmodulated transcripts using the EIMMo miRNA target prediction server 
(Supplementary Table S3). Among them, Transforming Acidic Coiled-Coil Containing 
Protein 1 (TACC1) and RAB5B resulted of particular interest. TACC1 is indeed a cancer-
related gene located on chromosome 8p11, amplified in breast cancer (23) and 
translocated in glioblastoma (24). RAB5, instead, is a small GTPase involved in 
intracellular trafficking and migration (25). Notably, TACC1 3’UTR contains two miR-22 
MREs, while RAB5B 3’UTR includes three of them (Supplementary Fig. 4D), suggesting 
that both genes could be directly and efficiently downmodulated by miR-22. Western blot 
analysis confirmed a strong TACC1 and RAB5B downregulation upon miR-22 induction, 
both in vitro and in vivo (Supplementary Fig. 4B and C). Moreover, sensor vectors 
expressing the mutagenized or the wild type miR-22 MREs of TACC1 and RAB5B 
3’UTRs showed that both genes were indeed miR-22 direct targets (Supplementary Fig. 
4E and F). 
 
TACC1 and RAB5B control the transformed properties of RMS cells 
To study the functional relevance of TACC1 in RMS pathogenesis, we first tested 
the effects of its downregulation in RMS cells. Interestingly, TACC1 silencing (Fig.  5A) 
impaired cell proliferation (Fig. 5B, C and F), promoted apoptosis (Fig. 5D and F) and 
inhibited soft-agar growth of both ERMS and ARMS cells (Fig. 5E). Conversely, TACC1 
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overexpression (Fig. 5G) partially rescued the anchorage-independent growth ability of 
miR-22-expressing RMS cells (Fig. 5H). 
RAB5 expression has been previously linked with tumor cell migration and 
invasion (26,27). However, RAB5 is encoded by three distinct paralogs: RAB5A, RAB5B 
and RAB5C. Interestingly, RAB5B is the prevalent isoform expressed in cells of both RMS 
subtypes (Fig. 6A and B). Thus, we silenced RAB5B in RMS cells (Fig. 6C) and explored 
whether RAB5B was involved in RMS cell motility. Wound healing assay showed that 
RAB5B silencing delayed wound closure at the evaluated time point (Fig. 6D and E), 
whereas RAB5B overexpression (Fig. 6F) enhanced migration towards the wounded area 
of miR-22-expressing RMS cells (Fig. 6G and H). Altogether, our data support a model in 
which the oncosuppressor role of miR-22 in RMS cells is at least in part due to TACC1 
and RAB5B downregulation. 
 
miR-22 prevents intrinsic resistance to MEK inhibition by intercepting ERBB3 
upregulation 
Comprehensive genomic analyses revealed that the RAS pathway is frequently 
mutated in ERMS tumors (8–10). Although the pharmacological inhibition of 
constitutively active RAS proteins remains challenging (28), small molecule inhibitors 
directed against the downstream ERK signalling offer an alternative RAS pathway-
targeted strategy. Nevertheless, the efficacy of MEK inhibitors in cancer patients is 
modest (29). This partial response has been frequently associated to the activation of 
compensatory feedback pathways involved in primary resistance (30,31). Notably, RD18 
cells harbour the constitutive active form of NRAS [NRAS Q61H (32)] and are relatively 
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resistant to MEK inhibition (30) (Fig. 7A). Considering the strong oncosuppressor 
potential of miR-22, we explored whether this miRNA could also play a role in preventing 
resistance to the MEK inhibitor Selumetinib. Intriguingly, miR-22 induction in 
combination with MEK inhibition potently blocked RD18 cell growth, enhancing the 
effects of the single treatment alone (Fig. 7A and C). Interestingly, a recent synthetic 
lethal screening approach revealed that a common mechanism of primary resistance to 
MEK inhibitors implicates ERBB3 upregulation (33). Also in RD18 cells, Selumetinib 
treatment resulted in a strong ERBB3 induction (Fig. 7B). Conversely, in the presence of 
miR-22, Selumetinib was unable to upregulate ERBB3 (Fig. 7B), suggesting that miR-22 
was interfering with ERBB3 expression. Accordingly, ERBB3 transcript contains a 
functional miR-22 MRE in the 3’UTR (Fig. 7D) and thus miR-22 can immediately 
intercept ERBB3 expression upon Selumetinib treatment. Finally, the combination 
treatment based on Selumetinib plus Lapatinib also enhanced Selumetinib-mediated soft-
agar growth inhibition (Fig. 7C), further confirming the functional relevance of ERBB3 
pathway activation in driving MEK inhibitor resistance. 
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Discussion 
 
In this work we performed miRNA NGS on primary RMS samples, RMS cell lines 
and normal skeletal muscles. The miRNA signature revealed a clear distinction between 
muscle and tumor specimens but, in contrast to a previous study (34), we were unable to 
distinguish the three histological categories included in our samples (ERMS, ARMS and 
PRMS), suggesting a common alteration in miRNA expression profile independently on 
RMS subtype.  
However, our miRNA expression profiling revealed that miR-378 and miR-22, 
together with other previously characterized myomiRs, were markedly underrepresented 
in RMS compared to normal muscle tissue. While miR-378 downregulation in RMS has 
been recently reported (19), the role of miR-22 has remained so far unexplored. The 
biological significance of miR-22 in cancer is still controversial and seems to be context 
specific. While it is generally considered as oncosuppressor (35–38), two recent papers 
support its oncogenic potential (39,40). Although miR-22 is ubiquitously expressed, it is 
particularly enriched in cardiac muscle, where it is involved in cardiac hypertrophy and 
remodelling (41,42). According to our data, miR-22 is also abundant in skeletal muscle 
and the muscle-specific transcription factor MyoD plays a critical role in regulating its 
expression in myogenic cells. While genome-wide analysis of MyoD binding regions in 
C2C12 myoblasts indicated its presence in the promoter of four miRNAs, including miR-
22 (21), here we identified the two paired sites upstream of miR-22, critical for both 
MyoD binding and transcription. As reported by others (43), MyoD is not functional in 
RMS despite its ability to associate with coactivators and to bind to DNA, and this could 
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explain why miR-22 expression is impaired in this tumor type. MyoD acts at two levels in 
myogenesis regulating first the block of cell proliferation and then muscle-specific gene 
expression (44). The mediators of the former effect are still poorly understood. Our data 
suggest that the anti-proliferative action of MyoD is accomplished, at least in part, post-
transcriptionally by miR-22. Indeed, when ectopically expressed in RMS cells of both 
embryonal and alveolar histology, miR-22 showed a prominent oncosuppressor potential 
by impairing cell proliferation, invasiveness and significantly increasing apoptosis. 
Besides its strong in vitro effect, miR-22 also displayed a remarkable anti-tumor effect in 
vivo, leading to a significant reduction of RMS growth and metastatic potential.  
By gene expression analysis in miR-22-expressing RD18 cells we identified 
TACC1 and RAB5B as promising miR-22-regulated candidates. TACC1 and RAB5, both 
acting on cytoskeleton dynamic, have been previously shown to be involved in cell 
transformation and in tumor dissemination. TACC1 was first identified as the sole coding 
sequence within the 8p11 breast cancer-associated amplicon and capable of transforming 
mouse fibroblasts by itself (23). Interestingly, a significant percentage of ERMS (up to 
92%) displays gain of the entire chromosome 8 (8–11), suggesting a possible oncogenic 
role for genes harboured in this chromosome. Conversely, RAB5 family members are 
critical trafficking molecules that directly influence several aspects of cell migration 
(26,27). Accordingly, modulation of either target genes influenced the transformed 
properties of RMS cells. While TACC1 was mainly involved in the regulation of RMS 
cell growth, RAB5B prevalently controlled RMS cell motility. Interestingly, RAB5A is 
also a predicted target of miR-206, and considering that all RAB5 members play a 
redundant role in actin cytoskeleton dynamic, we cannot rule out the possibility that more 
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complex circuits involving myomiRs and RAB5 genes are dysregulated in RMS 
pathogenesis. 
Since a single miRNA can potentially regulate hundreds of different transcripts, 
other targets are likely to contribute to miR-22 therapeutic efficacy. This concept is 
particularly relevant considering the widely accepted view that cancer is a Darwinian 
disease (31). Regrettably, the targeted therapy approach, less toxic than conventional 
chemotherapy, often gives rise to adaptive responses that result in resistance (31). In this 
context, a combination of a target therapy with a pleotropic miRNA with therapeutic 
potential could be beneficial in preventing mechanisms of resistance. We thus explored 
the functional relevance of miR-22 action in this setting. Interestingly, RD18 cells that 
harbor a constitutive active form of NRAS are modestly responsive to Selumetinib 
treatment and here we have shown that this is in part related to a feedback mechanism of 
compensation based on ERBB3 upregulation. Notably, ERBB3 was not present in our list 
of downregulated genes upon miR-22 induction, although it includes one functional MRE. 
This apparent discrepancy is based on the fact the profiling was performed in cells 
growing in medium without drugs. Indeed, ERBB3 upregulation was observed only upon 
Selumetinib treatment, and in this condition, the concomitant presence of miR-22 
efficiently interfered with the mechanism of resistance. Accordingly, we have shown that 
the combination of drugs (Selumetinib + Lapatinib) was more effective than single 
treatments. However this pharmacological strategy could still be inadequate to prevent the 
emergence of further resistance, especially in highly heterogeneous ERMS.  
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For this reasons, future therapeutic strategies against RMS could take advantage of 
using pleotropic oncosuppressor miRNAs (13,19,45–50), among which we now propose 
miR-22.  
Overall, our miRNA NGS and profiling reveal a novel miRNA network in which 
miR-22 plays a critical role by acting at multiple levels of regulation. Although drugs 
directed against individual miR-22 targets may provide useful alternative strategies in 
RMS, our data suggest that, once the problem of miRNA delivery will be overcome, 
miR-22 could represent an effective therapeutic option alone or in combination with 
targeted agents in primary tumors, distant metastases and to prevent drug-induced 
primary resistance.   
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Figure Legends 
 
Figure 1.  
miR-22 and -378 are downregulated in RMS but are induced during myogenic 
differentiation. A, section of the expression dendrogram including the top 8 
differentially expressed miRNAs in human skeletal muscles compared to RMS 
cells and tissues. Yellow indicates increased expression; black indicates reduced 
expression. B, Northern blot analysis on total RNA obtained from one muscle and 
one RMS sample. C and D, real-time PCR analysis in murine satellite cells (C) 
and C2C12 cells (D) grown in proliferation ‘P’ or differentiation medium ‘D’. E and 
F, real-time PCR analysis in inducible miR-206-expressing RD18 (NpBI-206) 
cells (E) and MyoD-expressing NIH 10T½ (NpBI-MyoD) cells (F) (induced, IND; 
non-induced, NI). Error bars, SD. 
 
Figure 2. 
miR-22 interferes with the transforming abilities of RMS cells. A and B, 
proliferation analysis of inducible miR-22-expressing RD18 (A) and RH30 (B) 
NpBI-22 cells (induced, IND; non-induced, NI). C and D, cell cycle distribution of 
RD18 (C) and RH30 (D) NpBI-22 cells (induced, IND; non-induced, NI). E and F, 
apoptosis assessment of RD18 (E) and RH30 (F) NpBI-22 cells (induced, IND; 
non-induced, NI). G, Western blot analysis in RD18 and RH30 NpBI-22 cells 
(induced, IND; non-induced, NI). H and I, quantification and representative 
images of soft-agar growth of RD18 (H) and RH30 (I) NpBI-22 cells (induced, 
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IND; non-induced, NI). J and K, invasiveness assessment of RD18 (J) and RH30 
(K) NpBI-22 cells (induced, IND; non-induced, NI). Error bars, SEM. *P<0.05; 
**P<0.01; ***P<0.001 (t test). 
 
Figure 3.  
miR-22 is transcriptionally regulated by MyoD. A, schematic representation of 
miR-22 promoter region. The putative binding sites for MyoD are indicated by 
black boxes. B and C, ChIP analysis of miR-22 promoter regions in NIH NpBI-
MyoD cells (induced, IND; non-induced, NI). Two independent oligo pairs were 
used for miR-22 promoter amplification (oligos A and oligos B). MCK and IgH 
enhancers were used as positive and negative controls respectively. Recruitment 
was relative to normal rabbit IgG. D, dual luciferase assay in NIH NpBI-MyoD 
cells (induced, IND; non-induced, NI) transfected with the indicated luciferase 
reporter constructs. Error bars, SD. *P<0.05; **P<0.01; ***P<0.001 (t test). 
 
Figure 4.  
miR-22 blocks RMS tumor growth and dissemination. A and B, tumor growth 
curve in nude mice subcutaneously injected with RD18 NpBI-22 cells. In A, half 
of the mice (n=6) were given doxycycline starting at the time of injection 
(induced, IND), while the rest remained untreated (non-induced, NI). In B, 
doxycycline was given to half of the mice (n=6) only when tumors become 
palpable (black arrow). C, immunohistochemical analysis of tumors recovered at 
the end of the treatment explained in B. D and E, Representative images of 
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whole mount lungs (D, upper panels) and kidneys (E, upper panels) recovered 3 
months after tail vein injection of RD18 NpBI-22 cells in nude mice (induced, IND; 
non-induced, NI). Lower panels show immunohistochemical analysis on sections 
from the tissues described above. Error bars, SEM. 
 
Figure 5. 
TACC1 promotes RMS cell proliferation, anchorage-independent growth and 
protects RMS cells from apoptosis. A, Western blot analysis in RD18 and RH30 
cells expressing the shRNA control (shCTRL) or TACC1-directed shRNA 
(shTACC1). B and C, proliferation analysis of RD18 (B) and RH30 (C) cells 
described in A. D, Apoptosis assessment of RD18 and RH30 cells described in A. 
E, quantification and representative images of soft-agar growth of RD18 and 
RH30 cells described in A after 2 weeks in culture. F, Western blot analysis in 
RD18 and RH30 cells described in A. G, Western blot analysis in RD18 NpBI-22 
cells expressing GFP (CTRL) or TACC1. H, quantification and representative 
images of soft-agar growth of RD18 NpBI-22 cells described in G and treated with 
doxycycline (induced, IND) for 2 weeks. Error bars, SEM. *P<0.05; **P<0.01; 
***P<0.001 (t test). 
 
Figure 6. 
RAB5B controls RMS cell migration. A and B, real-time PCR analysis of RAB5 
paralog transcripts in RD18 (A) and RH30 (B) cells. C, Western blot analysis in 
RD18 cells transfected with siRNA control (siCTRL) or with RAB5-directed 
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siRNAs (siRAB5A, B or C). D and E, representative images (D) and quantification 
(E) of wound closure of RD18 cells transfected with siCTRL or siRAB5B. F, 
Western blot analysis in RD18 NpBI-22 cells expressing GFP (CTRL) or RAB5B. 
G and H, representative images (G) and quantification (H) of wound closure of 
RD18 NpBI-22 cells maintained in presence of doxycycline (induced, IND) and 
expressing GFP (CTRL) or RAB5B. Error bars, SEM. *P<0.05 (t test). 
 
Figure 7.  
miR-22 intercepting ERBB3 counteracts the resistance to MEK inhibitors. A, 
Proliferation analysis of RD18 NpBI-22 cells induced (IND) or non-induced (NI) 
and treated with Selumetinib (SEL) or combination. B, Western blot analysis in 
RD18 NpBI-22 cells induced (IND) or non-induced (NI) and treated with Lapatinib 
(LAP), Selumetinib (SEL) or combinations for three days. C, quantification and 
representative images of soft-agar growth of RD18 NpBI-22 cells described in B. 
D, Dual luciferase assay in 293T cells transfected with the indicated luciferase 
reporter constructs (wild type, WT; mutated, MUT) along with miR-22. Error bars, 
SEM. *P<0.05; **P<0.01; ***P<0.001 (t test). 
 
 
 







